New drug combo shows promise against tough cancers
NCT ID NCT04349267
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an experimental drug called BMS-986315, alone or combined with other immunotherapies (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right dose. Researchers also looked at whether tumors shrank. The study is complete, but results are not yet widely reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-986315 (an experimental immunotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors like head and neck, lung, or kidney cancer.
What could go wrong
This is an early-phase trial with only 44 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution
Mexico City, Mexico City, 06100, Mexico
-
Local Institution - 0001
Germantown, Tennessee, 38138, United States
-
Local Institution - 0004
Toronto, Ontario, M5G 2M9, Canada
-
Local Institution - 0005
Montreal, Quebec, H2X 3E4, Canada
-
Local Institution - 0011
Vancouver, British Columbia, V5Z 4E6, Canada
-
Local Institution - 0013
Ottawa, K1H 8L6, Canada
-
Local Institution - 0014
Edmonton, Alberta, T6X 1E8, Canada
-
Local Institution - 0028
Sioux Falls, South Dakota, 57104, United States